180 Life Sciences Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Summary of Significant Accounting Policies [Abstract]

Schedule of Net Income (Loss) Per Share Basic and Diluted Weighted Average Shares Outstanding

The following table details the net loss per share calculation, reconciles between basic and diluted weighted average shares outstanding, and presents the potentially dilutive shares that are excluded from the calculation of the weighted average diluted common shares outstanding, because their inclusion would have been anti-dilutive:

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2023			2022			2023			2022
Numerator:
Net loss	$	(10,265,760	)	$	(21,486,978	)	$	(18,708,007	)	$	(16,983,981	)

Weighted average shares outstanding (denominator for basic earnings per share)		7,951,954			1,959,087			5,658,831			1,790,176

Weighted average shares and assumed potential common shares (denominator for diluted earnings per share, treasury method)		7,951,954			1,959,087			5,658,831			1,790,176

Basic loss per share	$	(1.29	)	$	(10.97	)	$	(3.31	)	$	(9.49	)
Diluted loss per share	$	(1.29	)	$	(10.97	)	$	(3.31	)	$	(9.49	)

Schedule of Anti Dilutive Common Shares

The following common share equivalents are excluded from the calculation of weighted average common shares outstanding, because their inclusion would have been dilutive:

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2023		2022		2023		2022
Options		-		162,957		-		162,957
Warrants		3,284,483		864,300		3,284,483		864,300
Total potentially dilutive shares		3,284,483		1,027,257		3,284,483		1,027,257